Seeking Alpha

Vir Biotechnology outlines accelerated hepatitis delta milestones and cash runway into mid-2027 as ECLIPSE 1 completes enrollment early

CEO Marianne De Backer highlighted the completion of enrollment in ECLIPSE 1, Vir’s first registrational Phase III study for hepatitis delta, ahead of internal projections. She indicated that "we now ...
Seeking Alpha

Vir Biotechnology outlines global patient recruitment and cash runway through mid-2027 amid hepatitis delta pipeline momentum

CEO Marianne De Backer highlighted several pipeline milestones, stating "we've made significant progress in our ECLIPSE registrational program for hepatitis delta," with first patients now enrolled in ...